0000000000942731

AUTHOR

Philippe Menasché

showing 2 related works from this author

Can bone marrow-derived multipotent adult progenitor cells regenerate infarcted myocardium?

2006

Objectives: To assess the functional effects of multipotent adult progenitor cells (MAPCs) transplanted in a rat model of chronic myocardial infarction. Methods: Forty-four rats underwent coronary ligation and, 14 days later, were randomly allocated to receive in-scar injections (5×106 cells/150 μL) of green fluorescent protein (eGFP)-transduced allogeneic MAPCs ( n =25) or culture medium (controls, n =19). Nine of the MAPC-treated hearts were employed for functional studies while the remaining 16 received cells co-labeled with Resovist™ and were only used for serial histological assessments. Left ventricular (LV) function was assessed echocardiographically before transplantation and 1 mont…

Graft RejectionPathologymedicine.medical_specialtyEndotheliumPhysiologyMyocardial InfarctionBone Marrow CellsRats Sprague-DawleyPhysiology (medical)MedicineAnimalsMyocardial infarctionTreatment FailureProgenitor cellbusiness.industryMultipotent Stem CellsMyocardiummedicine.diseaseMyocardial ContractionRatsTransplantationmedicine.anatomical_structureMultipotent Stem CellModels AnimalImmunohistochemistryFemaleBone marrowStem cellCardiology and Cardiovascular MedicinebusinessCardiovascular research
researchProduct

Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspecti…

2021

International audience; Extracellular vesicles (EV) are emergent therapeutic effectors that have reached clinical trial investigation. To translate EV-based therapeutic to clinic, the challenge is to demonstrate quality, safety, and efficacy, as required for any medicinal product. EV research translation into medicinal products is an exciting and challenging perspective. Recent papers, provide important guidance on regulatory aspects of pharmaceutical development, defining EVs for therapeutic applications and critical considerations for the development of potency tests. In addition, the ISEV Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics as well as the Exosomes C…

Quality ControlKnowledge management[SDV.BIO]Life Sciences [q-bio]/BiotechnologyBiological medicinal productsmedia_common.quotation_subjectDrug Compounding[SDV]Life Sciences [q-bio]Regulatory requirementsPharmaceutical ScienceMarketing authorizationExosomesChemistry Techniques Analytical03 medical and health sciencesExtracellular Vesicles0302 clinical medicineDrug DevelopmentDrug Stability[CHIM]Chemical SciencesHumansQuality (business)ComputingMilieux_MISCELLANEOUS030304 developmental biologymedia_commonCell-free therapySecretome0303 health sciencesClinical Trials as TopicClinical-grade EVScientific progressbusiness.industryDrug Administration RoutesExtracellular vesicleDrugs InvestigationalRegulatory affairs3. Good health[SDV.BIO] Life Sciences [q-bio]/BiotechnologyClinical trialEuropeAnalytics030220 oncology & carcinogenesisPosition paperMedicinal productsBusinessMicrovesicles
researchProduct